Open-label, add-on trial of cetirizine for neuromyelitis optica
Ilana Katz Sand(Icahn School of Medicine at Mount Sinai), Fred Lublin(Icahn School of Medicine at Mount Sinai), Lawrence J. Cook(University of Utah), John Rose(VA Salt Lake City Healthcare System), Shelly Ebel(University of Utah), Thomas M. Moran(University of Utah), Thomas Kraus(University of Utah), Michelle Fabian(University of Utah), Mirna Chehade(New York Proton Center), Madhan Masilamani(National Institutes of Health), Russell Telford(University of Utah), Colleen Farrell(University of Utah)
Cited by 26
Related Papers
How patients with multiple sclerosis acquire disability
|Brain|2022|508
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
|New England Journal of Medicine|2022|452
The Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence
|Current Nutrition Reports|2018|169
Daclizumab phase II trial in relapsing and remitting multiple sclerosis
|Neurology|2007|161
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
|New England Journal of Medicine|2024|107